key: cord-0861607-gnr3px4t
authors: nan
title: ACNP 60th Annual Meeting: Keyword Index
date: 2021-12-02
journal: Neuropsychopharmacology
DOI: 10.1038/s41386-021-01240-x
sha: aca423c0deae0c70df7c9ee84432fb2557848d08
doc_id: 861607
cord_uid: gnr3px4t

nan

coactivation pattern analysis . ................................................................. P389 delta opioid receptor . P805 Dementia ............................................................................. 37.3, 48, 48.2, 48.4 Dementia-related psychosis . .....................................................................48.3 Dendritic arborization . ............................................................................... P795 dendritic morphogenesis .......................................................................... P536 dendritic remodeling ....................................................................... P87, P598 Dendritic spines ............................................................................... P622 , P663 dentate gyrus . ................................................................................................P529 Depression ............................................................ 2.2, 2.5, 4, 4.2, 10.5, 16.3, 17.2, 21, 21.1, 21.4, 25.2, 37.3, 43, 43.3, 46.4, 51, 51.1, 51.3, 56, 56.2 , P11, P20, P48, P97, P176, P211, P221, P229, P230, P233, P238, P239, P240, P243, P244, P247, P252, P261, P265, P268, P280, P291, P295, P299, P306, P316, P324, P327, P333, P336, P342, P343, P352, P368, P377, P390, P404, P406, P606, P762 Depression and Anxiety . .......................................................10, 37.2, P109, P242, P338, P379, P382 depression and obesity . ............................................................................ P386 Depression Inflammation Cytokine ..................4.4 , P297, P361, P370 depression recurrence risk . depressive disorders . .................................................................................. P169 depressive symptoms ........................................................ 51.2, P298, P359 development .......................................................................................... 4.1, P640 Developmental .......................................................................... 54 , P172, P704 Developmental Psychopathology ........................................................... P43 Developmental trajectory ......................................................................... P534 Developmental transcriptome .................................................................11.1 Diagnosis ..........................................................................................................P575 Differential susceptibility .......................................................................... P140 Diffusion Tensor Imaging (DTI) . .........................................27.1, P57, P85, P197, P376, P586, P752 Diffusion Weighted Imaging . ........................................P487 , P565, P605 Digital phenotyping . ................................................................................... P214 digital psychiatry .......................................................................................... P228 Dimensional child psychopathology . ....................................... 26.4, 28.5 dimensional psychopathology . ................................................................ P85 dimensions .........................................................................................................38.3 dimethyltryptamine ..................................................................................... P365 Discrimination ..................................................................................................... 27 Disease risk prediction . .................................................................................. 3.1 disinhibition ....................................................................................................1, 1.2 disruptive behavior disorders . ................................................................ P156 diverse populations ......................................................................................... 1.2 diversity ............................................................................................. 40, 49, P790 DLPFC ....................................................................................................P567, P760 DNA ............................................................................................ 48.1, P566, P575 DNA hydroxymethylation ........................................................................... P61 DNA Methylation ...............................................................27, 31, P61, P227,  P362, P377, P479, P778 DNMT . .................................................................................................................P755 Dopamine .............................................................. 6.2, 22.4, 29.3, 30.4, 39.3, 44.4, 51.1 , P6, P47, P109, P129, P153,  P165, P177, P191, P205, P268, P282,  P330, P340, P388, P413, P427, P446,  P535, P547, P597, P658, P679,  P689 , P691, P709, P710, P823 Dopamine (D2, D3) receptors . ............................................................... P699 dopamine D3 receptors ............................................................... P642, P770 Dopamine D4 Receptor ............................................................................. P590 Dopamine function ...................................................................................... P668 dopamine receptor type 2-expressing striatal medium spiny neuron . ........................................................................... .................................................................................42.4 Dopaminergic system ................................................................................. P650 dorsal caudate ............................................................................................... P165 Dorsal Hippocampus .........................................................P108, P269, P768 dorsal raphe ........................................................................................ 56.2, P194 Dorsal Root Ganglia .................................................................................... P419 Dorsal striatum ................................................................................. P662, P702 dorsal visual stream .................................................................................... P439 dorsolateral prefrontal cortex ................................. 6.5, 37.5, P484, P502 dorsolateral striatum .....................................................................................10.4 Dorsomedial striatum ...................................................................................50.3 Doublecortin ...................................................................................................P217 DRD1 ...................................................................................................................P679 DRD2 ...................................................................................................................P679 DREADDs .............................................................................................. P109, P277 Drosophila ........................................................................................................P229 drug abuse .......................................................................................... P709, P720 Drug Development ......................................................................... P225, P472, P563 drug discrimination ..................................................................................... P584 Drug metabolism ............................................................................. P664, P694 Drug Relapse ......................................................................... 45.3, P657, 55.4 , P623 D-serine . .................................................................................. P462, P514, P525 Dual orexin receptor antagonist . ....................................20.3, 20.4, 20.5 , P185, P581, P582, P584, P764 duloxetine . .. 25.3, 27.3, 54.2 Early life stress . ................................................ 10, 16.3, 25.2, 28, 29, 29.5, 44, 44.5, 54.1, 54.3 , P44, P132, P134, P254, P294, P316, P675, P684, P700 early onset psychosis . ......................................................... 10.3, 25.4, 29.5, 54, 54.3 , P108, P128, P157, P665, P737 early-life stress . ................................................................................... P48, P430 eating ..11.4, 14.3, 14.4 , P186 ecological momentary assessment . ..... 9, 9.1, 13.2, 21.4 , P313, P522 EEG biomarkers . ....................................... 9.2, 26.2, 57, 57.2, P314, P476 EEG .. 37.4, 57.4 .....8, 8.3 Efficacy and

. P283 effort based decision making task . ...........................P122, P310, P498 Effort .. 11.2, 45, P182, P205, P216, P472, P539, P702, P720, P751 ................................................................ P65, P788 emotion .............................................................................................................P465 Emotion Circuitry ............................................................................................14.2 emotion processing ..................................................................................... P164 emotion regulation ...................................................................................... P820 Emotional dysregulation ............................................................................. P72 Emotional empathy ........................................................................ P528, P690 Emotional regulation ..................................................... 14, 25.3, 43.4, 53.2 Emotional stress . ........................................................................................... P780 emulated target trial ................................................................................... P312 endocannabinoid system .............................................................. P59, P111 Endocannabinoids ......................................................P40, P49, P468, P696 endophenotypes ..................................................................................... 38, 38.5 Endothelial function . ..................................................................................... P72 ..... 48.2 , P120, P133, P544, P550 epigenetic age acceleration . ................................................................... P362 Epigenetic biomarkers .................................................................................25.1 Epigenetic Modification .................................................................... 16.2, P75 Epigenetics ........................................................ 2.2, 10.3, 16, 16.4, 16.5, 25, 29, 29.2, 29.5, 31.2 , P3, P36, P80, P113, P294, P375, P479, P629, P664, P708, P715, P744, P756, P778 epigenomics . ...................................................................................................P269 epilepsy ................................................................................................ P415, P423 equity ....................................................................................................................... 40 ERP .......................................................................................................................P525 Error processing ............................................................................... P436, P797 Escitalopram ....................................................................................................P305 Esketamine ......................................................................................................... P83 estradiol ......................................................................... 10.4, 53.3 , P327, P351 estrogen receptor . ........................................................................................ P327 estrogen therapy ............................................................................................... 53 ethanol ..................................................................................................P599, P644 ethanol intake ................................................................................................ P757 ethics ............................................................................................................... 12, 32 eugenics ............................................................................................................P540 event-related potentials ............................9.3 , P187, P470, P669, P811 evidence-based approach . ....................................................................... P773 EWAS ...................................................................................................................P377 excessive sleepiness ......................................................................................56.1 excitability .......................................................................................................... P75 excitation-inhibition balance . ................................................................. P471 executive function ...................................................... 54.2 , P8, P172, P195 Exercise . .................................................................................................................. P3 Experience dependent plasticity . ...........................................................54.1 experimental design ........................................................................................ 58 Experimental Therapeutics .............................................................. 47, P476 exploration .......................................................................................................P792 explore-exploit dilemma . ............................................................. P719 , P792 Exposure therapy . ........................................................................................... P54 extended amygdala ......................................................................... P39, P825 Externalizing behavior ..................................................................................54.4 externalizing disorders . .............................................................................. P822 Extinction ............................................................................................... P66, P657 Extinction and Reinstatement ................................................................ P596 Extinction learning ......................................................................................... P54 extracellular matrix ......................................................................... P301, P628 Extracellular vesicles ....................................................................... P248, Facial emotion processing . ............................................P304 , P588, P670 factor analysis . ................................................................................................P289 familial risk ................................................................P363 , P397, P398, P399 familial risk of bipolar disorder . ............................................................ P288 fast scan cyclic voltammetry . .................................................... P650, P41, P84, P239 Fear conditioning ............................................ P52 , P60, P89, P130, P347 Fear conditioning and extinction . ..........................P31, P54, P55, P59, P76, P209, P444 Fear extinction . ...................................................................................... P87, P92 fear generalization ......................................................................................... P40 Fear learning ..................................................................... 56.4 , P30, P75, P96 Fear physiology . ............................................................................................ P444 fear-potentiated startle . ................................................................ P130, P185 Fecal microbiota transplant ..................................................................... P334 Feedback negativity ......................................................................................57.2 Feeding ........................................................................................... 30, 30.3 , P509 feeding behavior . ............................................................................. 11.3, P195 females ..............................................................................................................P309 Fentanyl ........................................................................... 20 , P598, P647, P718 fetal alcohol spectrum disorder . ..............................................P138, P664 Fetal Brain Development ............................................................................44.2 Fetal Origins ......................................................................................................25 .1 fiber photometry . .......................... P90 , P136, P347, P446, P534, P676 fibromyalgia . ...................................................................................................P176 first episode . ......................................................................................................13.2 first episode psychosis . ................................................................. 13.3, P455, P474, P505, P515, P516, P531 first-episode schizophrenia . ..................................................................... P524 FKBP5 ....................................................................................................... P45, P170 Flanker Task .....................................................................................................P670 fluoxetine .............................................................................................. 50.2, P292 FMR1 premutation ....................................................................................... P428 fMRI Biomarkers ............................................................................................ P304 fMRI Effective Connectivity . ..................................................................... P439 fMRI Functional Connectivity .................................................................. P593 fMRI resting state . ........................................................................... P148, P726 fNIRS ....................................................................................................................P631 focused ultrasound ............................................................P729 , P793, P811 food craving . ...................................................................................................P335 food deprivation ........................................................................................... P750 food intake . .....................................................................................................P600 fragile X syndrome . ..................................................................................... P173 Free water imaging . ....................................................................... P376, , P403 functional brain network . ......................................................................... P455 functional connectivity ..................................................... P74, P112, P459, P469, P568, P825, P828 functional disability . .................................................................................... P319 Functional imaging ........................................................................................30.3 functional impairment . ................................................................. P275, P298 Functional MRI (fMRI) 2.5, 7, 9.1, 14.4, 26, 27.1, 37.2, 37.4, 51.1, 53, 55.3, 60.3 , P28, P59, P70, P76, P92, P137, P168, P193, P241, P243, P253, P277, P291, P307, P325, P326, P353, P403, P418, P448, P551, P570, P571, P625, P652, P690, P769, P788, P797, P804, P822 functional near-infrared spectoscopy . ..................................................... 26 functional neuroimaging .....................................................14.3, 53.3, P55, P444, P456 imaging ..................................................................................................... 54, immediate early gene . .................................................................. P612, P635 Immune ........................................................................................................... .. P47 in vivo calcium imaging . ............................................ 11.3 , P39, P40, P50, P67, P438, P597 In vivo Imaging . ............................................................. 30.2, 30.4 , 41, P422 In vivo microscopy . ........................................................................................50.2 incentive motivation . .................................................................................. P697 inclusion and exclusion . ............................................................................................ P256 insomnia ............................................................................... 20.5, 51, 51.4 , P99, P581, P606, P764 insomnia disorder . ....................................................................................... P582 instrumental learning ................................................................................. P663 Insula ................................................................ 55.2 , P145, P237, P456, P760 insulin . .............................................................. 44 Interbrain Synochrony ................................................................................ P809 Intergenerational Transmission ............................................................. P149 Intergenerational transmission of trauma . Intermittent Access self-administration . ................... 20.3, P643, P659 internalizing disorders .................................................................... 54.4, intravenous drug self-administration . ......................P608, P624, P642 intrinsic EEG activity ......................................................................................60.4 intrinsic excitability . .......................................................................................29.2 intrinsic motivation . ..................................................................................... P571 ion channels .......................................................................... P308, P431, P539 irradiance ..........................................................................................................P286 irritability ......................................................... 47, 53, 53.1, 53.2, 53.3 , P674 Irritability/Aggression . .................................................................... juvenile critical period . .............................................................................. P108 juvenile social isolation . P278, P379, P766, P779 Kappa Opioid Receptor Antagonist .................................................... P731 Ketamine ........................................................................... 25.2, 50.3, P66, P68,  P102, P233, P293, P328, P400, P402, P405, P458 Ketorolac . ..........................................................................................................P102 kinase inhibitor .............................................................................................. P344 kinome array ...................................................................................... P550, P559 Kinomics ............................................................................................................P322 kinship ..........................................................................................................11, 11.2 kratom ................................................................................................................P667 Kv3 channels ...................................................................................................P460 Kynurenic acid ....................................................... 6.3, 6.4, 6.5 , P557, P572 Kynurenine pathway . .............................................................6, 6.3, 6.4, 51.3 L1000 ..................................................................................................................P262 Lactate ................................................................................................................P284 Language ............................................................................................. P496, P654 Late-life Depression ............................................................. 8.1, 8.2 , P9, P11, P227, P248, P354 latency of acoustic startle . ....................................................................... P545 Latent class analysis ....................................................................... P238, P289 Lateral Habenula ...........................................42.1, P73, P194, P293, P752 Lateral hypothalamus .......................................................... 30.3, 39.4 , P194 lateral septum . .................................................................. 11, 11.2, 11.3, 11.4 Latin America . P44 Leptin Resistance .......................................................................................... P509 leukocyte telomere length . ......................................................................... 4.3 levomilnacipran ............................................................................................. P367 LgDel ...................................................................................................................P570 Lifetime stress .................................................................................... 44.3, P456 linguistic markers ........................................................................................... P98 lipid oxidation ................................................................................................ P567 lipid rafts ...........................................................................................................P369 lipids .......................................................................................................P189, P361 lithium ...................................................................................................P381, P390 local field potentials . .....................................................................................57.3 Locus coeruleus (LC) . .............................................................................P9 , P10 Long Access self-administration . ............................................................20.2 Long Term Potentiation ............................................................................ P462 Long-acting injectable antipsychotics . ............................19, 60.3 , P541 longitudinal analysis . ...................................................................... 26.2, P135 Longitudinal MRI ............................................................................ P107, P810 longitudinal study ............................................................................. P85, P763 Loss ........................................................................................................................39.5 LQFM032 ...........................................................................................................P407 LSD ..........................................................................................................P682, P796 LSD microdosing .............................................................................. P818, P824 lumateperone .................................................................................................P319 M5 muscarinic receptor ............................................................................ P330 Macaque ............................................................................................... P165, P794 machine learning .................................................................. 21.4, 39.4, P112,  P318, P474, P496 machine learning classification . .....................P198 , P421, P473, P542 Machine learning clustering . ....................................................................45.4 Macrophage ......................................................................................................52.2 MADRS ...............................................................................................................P223 Magnetic Resonance Imaging (MRI) . ............................... 16.5, 23, 27.2, 37.3 ........................................................................ P289 magnetoencephalography .......................................................... P454, P531 Major depression ...................................................P215, P226, P396, P575 Major Depression Disorder ...........................................P281, P314, P322,  P350, P384, P389, P401 Major Depressive Disorder (MDD) . ................................21.2, 21.3, 31.5 , P51, P66, P83, P94, P179, P218, P222, P223, P224, P235, P241, P245, P246, P251, P259, P264, P271, P301, P303, P305, P312, P326, P353, P357, P359, P371, P374, P415, P819, P392 maladaptive feeding . .................................................................................. P190 mania ........................................................................................ P270, P341, P505 marijuana ............................................................................................. P616, P653 Marijuana Policy ............................................................................................ P481 marmoset ........................................................................................................... P13 mast cells .............................................................................................................. 4.1 MAT .....................................................................................................................P701 maternal brain ............................................................................................... P690 Maternal Depression .....................................................................................26.4 maternal immune activation . .......................................P165, P405, .................................................. P628 MDMA ....................................................................................................... 2.3 , P682 mechanism-based biomarkers . ........................................................4, 4.2, 5 mechanisms ......................................................................................................... 37 Medial Orbitofrontal Cortex ........................................... 35.4, P332, P785 Medial Prefrontal Cortex ........................................................ 22.4, 45, 45.2, 50.3 , P12, P89, P109, P195, P213, P300, P537, P599, P612, P659, P795, P802, P808, P830 Medial septum . .............................................................................................. P710 Medical Marijuana ........................................................................... P606, P633 medication development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 medication-naive first episode psychosis . .........................................60.2 medications .......................................................................................................... 17 Medium Spiny Neuron ............................................ 50.2, P67, P190, P3, P49, P71, P406, P748 Memory and Learning ................................................................................. P15 Memory Encoding and Retrieval .......................................................... P663 Memory engram cell ....................................................................... P75, P528 memory reconsolidation ........................................................................... P768 menopause .................................................................................... 4.3, 56.3, P18 mental disorder ............................................................................................... 23.3 Mental health disorders . ........................................................................... P181 mental health service use . ....................................................................... P827 mental illness ...................................................................................................... 3.1 mentoring .............................................................................................................. 40 mesolimbic reward circuitry . ........................................P182, P190, P592, P617, P730 meta-analysis . ............................................... P97 , P133, P520, P742, P812 metabolic function . ........................................................................................ P53 metabolism ......................................................................................................P648 metabolites ......................................................................................................P740 metabolomics .................................................................................... P189, P349 Methamphetamine ...........................................20.2, 34, 34.4, 34.5 , P619, P624, P652, P705, P712 methamphetamine seeking . ................................................................... P641 Methocinnamox ............................................................................................ P718 ........................................ P55, P505, P654, P679, P699 mgluR5 ................................................................................................................. P51 mice ........................................................................................................P166, P815 microbiome .......................................................................... 28.2, 33, 53, P334 microbiota ........................................................................................................P334 Microbiota-gut-brain axis . ............................................................ P334, P715 Microdialysis ....................................................................................................P650 microglia .......................................................................... 28.2, 44.4, 52.2, P24,  P114, P129, P278, P306, P360, P379, P416, P558, P624, P644 microglia engulfment . ..................................................................................54.1 microPET ...........................................................................................................P134 MicroRNA ..........................................................................................................P747 midbrain ............................................................................................................P122 mild cognitive impairment due to AD . ............................................. P314 Mild Traumatic Brain Injury ....................................................................... P88 Mindfulness Meditation ............................................................................. P145 miRNA ................................................................................................................P217 Mirror Neuron .................................................................................................P528 Mismatch Negativity ...................................................................... P464, P514 Mitochondria .................................... P23, P244, P255, P275, P416, P637 Mitochondrial DNA ........................................................................................44.3 mitochondrial dysfunction ....................................................................... P254 mitochondrial genetics ................................................................................... 44 Mitochondrial Respiration ............................................................. P23, P302 Mitophagy ........................................................................................................P395 MMN ...................................................................................................................P525 model systems ............................................................................................... P706 Moderators .........................................................................................................21.3 modulator .........................................................................................................P493 Molecular imaging .........................................................................................16.5 molecular neuroscience ............................................................... P173, P293 Molecular profiling .........................................................................................11 .1 monetary incentive delay task . ............................................................. P193 monkey ..............................................................................................................P380 monoamine oxidase B P425, P767 Monoamine Transporters . ..........................................................................21.1 Monoiodoacetate Model of Osteoarthritis . ...................................... P432 Mood ...........................................................................P285 , P391, P415, P738 Mood and cognition . .................................................................................. P668 mood disorders ..................................................................P121, P217, P237, P298, P345, P364, P373, P385 morphine . ............................................................................................ P592, P745 Mortality ................................................................................................................. P1 motivated behavior ............................................................................... 11, 11.4 motivation ................................................................... P73, P122, P294, P534 motivational ....................................................................................................P780 motor activity .................................................................................................P121 mouse ................................................................................................................... P13 mouse genetics ............................................................................................. P735 Mouse models . .................................... 28, 34.4, P292, P295, P426, P596 mPFC ....................................................................................................... 39.4 , P134 MR spectroscopy . ................................................................P385, P483, P538 MRSI ....................................................................................................................P284 mtDNA ...............................................................................................................P395 mTORC1 P273 Multi-electrode arrays . .................................................................................. P47 multimodal data ............................................................................................ P131 Multimodal Neuroimaging .........................................................................37.5 Multi-omics . .....................................................................................................P349 multivariate ......................................................................................................P106 multivariate analysis ........................................................... 38.3 , P469, P703 mu-opioid receptor agonist . ................................................................... P667 mu-opioid receptor binding potential . .............................................. P391 mu-opioid receptors ......................................................... 42.2 , P339, P600, P732, P819 Muscarinic agonist . ...................................................................................... P510 muscarinic M4 P493, P500

P58, P68, P251, P760 Cortisol response to stress

2.3, P74, P467, P475, P814 defensive and motivated behaviors

59, P19, P206 health policy

20, 20.2, P625, P628, P673 heroin self-administration

60th Annual Meeting: Keyword Index

43, 43.2, P447, P473 Neurofibrillary tangle

1, 30.5, P280, P759 neuromodulators

P464 Neuronal stem cells (NSCs)

1, 57.4, P428 Neuropsychiatric Disorders [Schizophrenia, Parkinson's Disease, Major Depressive Disorder]

P589, P623, P815 nicotine addiction

35.2, P78, P201 non-invasive brain stimulation

P429, P432 non-parametric item response theory

Obsessive Compulsive Disorder

P434 obsessive-compulsive spectrum disorders (OCDS)

30, 30.3, 42, P176, P408, P606, P612, P633, P701 Pain sensitivity

26, 26.2, 26.3, P206 parietal cortex

P211, P586, P678, P700 Perceptual decision-making

3, P132, P363, P540, P819 polygenic risk scores

3, 34.3, 52.2, P411 projection targets

1, 27.3, 59 Racism and discrimination stress

55.5, P350, P502 raphe nucleus

Rare genetic variation

43, 43.2, 43.3, 43.4, P122, P145, P467 recognition memory

P718 repetitive transcranial magnetic stimulation (rTMS)

P363 Risk Evaluation and Mitigation Strategy (REMS)

48.1, P566, P575 serious mental illness

42.1, P192 serotonin and norepinephrine reuptake inhibitor

11.1, 29, 42.2, P95, P138, P290, P339, P688, P689 single-cell sequencing

16.2, P154 social determinants of health

14.3, P126, P757, P802 social isolation

44.5, P42, P70, P162, P474 structural racism

2, 2.2, 45.5

29.3, 39, P123, P134, P360, P657, P730, P794 transcutaneous auricular vagus nerve stimulation (taVNS)

P311 Translational biomarker approaches to drug development

Traumatic Brain Injury

4, P245, P376 treatment-resistant late life depression

5, 57.5, P594, P689 ventral visual stream

6.5, P568, P620, P712 working memory fMRI